Published in J Med Chem on April 22, 2010
New β-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother (2013) 1.47
Systematic analysis of metallo-β-lactamases using an automated database. Antimicrob Agents Chemother (2012) 1.08
Elucidating the role of Trp105 in the KPC-2 β-lactamase. Protein Sci (2010) 1.07
Assay platform for clinically relevant metallo-β-lactamases. J Med Chem (2013) 0.99
The sequence-activity relationship between metallo-β-lactamases IMP-1, IMP-6, and IMP-25 suggests an evolutionary adaptation to meropenem exposure. Antimicrob Agents Chemother (2012) 0.92
QM/MM studies of monozinc β-lactamase CphA suggest that the crystal structure of an enzyme-intermediate complex represents a minor pathway. J Am Chem Soc (2010) 0.89
Understanding the determinants of substrate specificity in IMP family metallo-β-lactamases: the importance of residue 262. Protein Sci (2014) 0.85
B1-Metallo-β-Lactamases: Where Do We Stand? Curr Drug Targets (2016) 0.82
Biochemical characterization of IMP-30, a metallo-β-lactamase with enhanced activity toward ceftazidime. Antimicrob Agents Chemother (2013) 0.79
Biapenem inactivation by B2 metallo β-lactamases: energy landscape of the hydrolysis reaction. PLoS One (2013) 0.78
An altered zinc-binding site confers resistance to a covalent inactivator of New Delhi metallo-beta-lactamase-1 (NDM-1) discovered by high-throughput screening. Bioorg Med Chem (2013) 0.78
Protein variants form a system of networks: microdiversity of IMP metallo-beta-lactamases. PLoS One (2014) 0.78
Carbamylmethyl Mercaptoacetate Thioether: A Novel Scaffold for the Development of L1 Metallo-β-lactamase Inhibitors. ACS Med Chem Lett (2017) 0.77
Prevalence and Fate of Carbapenemase Genes in a Wastewater Treatment Plant in Northern China. PLoS One (2016) 0.76
Elucidating the Role of Residue 67 in IMP-Type Metallo-β-Lactamase Evolution. Antimicrob Agents Chemother (2015) 0.76
Meropenem and chromacef intermediates observed in IMP-25 metallo-β-lactamase-catalyzed hydrolysis. Antimicrob Agents Chemother (2015) 0.76
The Role of Active Site Flexible Loops in Catalysis and of Zinc in Conformational Stability of Bacillus cereus 569/H/9 β-Lactamase. J Biol Chem (2016) 0.75
Clustal W and Clustal X version 2.0. Bioinformatics (2007) 126.47
TreeView: an application to display phylogenetic trees on personal computers. Comput Appl Biosci (1996) 56.57
The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci (1980) 17.57
Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother (2001) 16.97
Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev (2007) 15.82
Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev (1996) 13.25
Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev (2005) 12.07
Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob Agents Chemother (2000) 10.05
Cloning and characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother (1999) 9.01
Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance. Antimicrob Agents Chemother (1994) 8.64
Antibiotics for emerging pathogens. Science (2009) 7.39
PCR detection of metallo-beta-lactamase gene (blaIMP) in gram-negative rods resistant to broad-spectrum beta-lactams. J Clin Microbiol (1996) 6.68
Characterization of the metallo-beta-lactamase determinant of Acinetobacter baumannii AC-54/97 reveals the existence of bla(IMP) allelic variants carried by gene cassettes of different phylogeny. Antimicrob Agents Chemother (2000) 5.26
The changing epidemiology of resistance. J Antimicrob Chemother (2009) 5.13
Has the era of untreatable infections arrived? J Antimicrob Chemother (2009) 4.83
Molecular characterization of SPM-1, a novel metallo-beta-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. J Antimicrob Chemother (2002) 4.80
Functional characterization of the antibiotic resistance reservoir in the human microflora. Science (2009) 4.78
Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity. Chem Rev (2005) 4.48
Standard numbering scheme for class B beta-lactamases. Antimicrob Agents Chemother (2001) 4.36
The 3-D structure of a zinc metallo-beta-lactamase from Bacillus cereus reveals a new type of protein fold. EMBO J (1995) 4.30
Structure of In31, a blaIMP-containing Pseudomonas aeruginosa integron phyletically related to In5, which carries an unusual array of gene cassettes. Antimicrob Agents Chemother (1999) 4.24
Beta-lactamase-mediated imipenem resistance in Bacteroides fragilis. Antimicrob Agents Chemother (1986) 3.87
Sequence analysis of ARI-1, a novel OXA beta-lactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92. Antimicrob Agents Chemother (2000) 3.85
Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 in an Enterobacter sp. Antimicrob Agents Chemother (2004) 3.82
Separation, purification and properties of beta-lactamase I and beta-lactamase II from Bacillus cereus 569/H/9. Biochem J (1974) 3.82
Crystal structure of the wide-spectrum binuclear zinc beta-lactamase from Bacteroides fragilis. Structure (1996) 3.75
ARI 1: beta-lactamase-mediated imipenem resistance in Acinetobacter baumannii. Int J Antimicrob Agents (1993) 3.24
OXA-type carbapenemases. J Antimicrob Chemother (2006) 3.15
blaVIM-7, an evolutionarily distinct metallo-beta-lactamase gene in a Pseudomonas aeruginosa isolate from the United States. Antimicrob Agents Chemother (2004) 3.13
Nosocomial outbreak of carbapenem-resistant Pseudomonas aeruginosa with a new bla(IMP) allele, bla(IMP-7). Antimicrob Agents Chemother (2002) 2.97
Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis (2008) 2.87
Update of the standard numbering scheme for class B beta-lactamases. Antimicrob Agents Chemother (2004) 2.83
Characterization and sequence of the Chryseobacterium (Flavobacterium) meningosepticum carbapenemase: a new molecular class B beta-lactamase showing a broad substrate profile. Biochem J (1998) 2.78
Class A carbapenemases. J Antimicrob Chemother (2007) 2.72
Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect (2005) 2.71
An evolutionary classification of the metallo-beta-lactamase fold proteins. In Silico Biol (1999) 2.58
Crystal structure of the IMP-1 metallo beta-lactamase from Pseudomonas aeruginosa and its complex with a mercaptocarboxylate inhibitor: binding determinants of a potent, broad-spectrum inhibitor. Biochemistry (2000) 2.54
Metallo-beta-lactamases: novel weaponry for antibiotic resistance in bacteria. Acc Chem Res (2006) 2.46
Biochemical characterization of the metallo-beta-lactamase CcrA from Bacteroides fragilis TAL3636. Antimicrob Agents Chemother (1992) 2.40
First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States. Antimicrob Agents Chemother (2005) 2.29
Clinically significant carbapenemases: an update. Curr Opin Infect Dis (2008) 2.01
Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin Infect Dis (2006) 1.99
The three-dimensional structure of VIM-2, a Zn-beta-lactamase from Pseudomonas aeruginosa in its reduced and oxidised form. J Mol Biol (2007) 1.94
On the mechanism of the metallo-beta-lactamase from Bacteroides fragilis. Biochemistry (1999) 1.94
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. Antimicrob Agents Chemother (2009) 1.88
Plasmid-mediated carbapenem-hydrolysing beta-lactamase KPC-2 in carbapenem-resistant Serratia marcescens isolates from Hangzhou, China. J Antimicrob Chemother (2007) 1.84
Biochemical characterization of the acquired metallo-beta-lactamase SPM-1 from Pseudomonas aeruginosa. Antimicrob Agents Chemother (2003) 1.75
Zinc as a cofactor for cephalosporinase from Bacillus cereus 569. Biochem J (1966) 1.74
Role of penicillin-binding proteins in bacterial cell morphogenesis. Curr Opin Microbiol (2003) 1.66
Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs (2008) 1.51
Two decades of imipenem therapy. J Antimicrob Chemother (2006) 1.46
Virtual screening against metalloenzymes for inhibitors and substrates. Biochemistry (2005) 1.46
Phylogenetic analysis shows that the OXA beta-lactamase genes have been on plasmids for millions of years. J Mol Evol (2002) 1.43
Antibiotic sensitization using biphenyl tetrazoles as potent inhibitors of Bacteroides fragilis metallo-beta-lactamase. Chem Biol (1998) 1.41
Shape signatures: a new approach to computer-aided ligand- and receptor-based drug design. J Med Chem (2003) 1.39
IMP-1 carbapenemase detected in an Acinetobacter clinical isolate from the UK. J Antimicrob Chemother (2002) 1.39
Succinic acids as potent inhibitors of plasmid-borne IMP-1 metallo-beta-lactamase. J Biol Chem (2001) 1.38
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family. Antimicrob Agents Chemother (2008) 1.36
ADANSONIAN ANALYSIS AND DEOXYRIBONUCLEIC ACID BASE COMPOSITION OF SERRATIA MARCESCENS. J Bacteriol (1965) 1.33
Antibiotic recognition by binuclear metallo-beta-lactamases revealed by X-ray crystallography. J Am Chem Soc (2005) 1.30
First occurrence of a Pseudomonas aeruginosa isolate in the United States producing an IMP metallo-beta-lactamase, IMP-18. Antimicrob Agents Chemother (2006) 1.30
Imipenem: first of a new class of beta-lactam antibiotics. Ann Intern Med (1985) 1.30
Crystallographic investigation of the inhibition mode of a VIM-2 metallo-beta-lactamase from Pseudomonas aeruginosa by a mercaptocarboxylate inhibitor. J Med Chem (2007) 1.27
Structural basis for the broad-spectrum inhibition of metallo-beta-lactamases by thiols. Org Biomol Chem (2008) 1.26
Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach. Chem Biol Interact (2006) 1.26
Successful molecular dynamics simulation of the zinc-bound farnesyltransferase using the cationic dummy atom approach. Protein Sci (2000) 1.26
Identification of residues critical for metallo-beta-lactamase function by codon randomization and selection. Protein Sci (2001) 1.23
New predictive models for blood-brain barrier permeability of drug-like molecules. Pharm Res (2008) 1.20
Impact of remote mutations on metallo-beta-lactamase substrate specificity: implications for the evolution of antibiotic resistance. Protein Sci (2005) 1.20
Emergence of IMP-4 metallo-beta-lactamase in a clinical isolate from Australia. J Antimicrob Chemother (2004) 1.19
blaVIM-2 and blaVIM-7 carbapenemase-producing Pseudomonas aeruginosa isolates detected in a tertiary care medical center in the United States: report from the MYSTIC program. J Clin Microbiol (2006) 1.16
Docking for fragment inhibitors of AmpC beta-lactamase. Proc Natl Acad Sci U S A (2009) 1.13
Ertapenem: a new carbapenem. Expert Opin Investig Drugs (2001) 1.12
Hybrid QM/MM and DFT investigations of the catalytic mechanism and inhibition of the dinuclear zinc metallo-beta-lactamase CcrA from Bacteroides fragilis. J Am Chem Soc (2005) 1.12
Thiomandelic acid, a broad spectrum inhibitor of zinc beta-lactamases: kinetic and spectroscopic studies. J Biol Chem (2001) 1.12
Modeling domino effects in enzymes: molecular basis of the substrate specificity of the bacterial metallo-beta-lactamases IMP-1 and IMP-6. Biochemistry (2003) 1.11
Insight into the mechanism of the IMP-1 metallo-beta-lactamase by molecular dynamics simulations. Protein Eng (2003) 1.07
Dissemination of Acinetobacter baumannii clones with OXA-23 Carbapenemase in Colombian hospitals. Antimicrob Agents Chemother (2007) 1.06
Inhibition of OXA-1 beta-lactamase by penems. Antimicrob Agents Chemother (2008) 1.04
Shape Signatures: speeding up computer aided drug discovery. Drug Discov Today (2006) 1.03
Coordination geometries of metal ions in d- or l-captopril-inhibited metallo-beta-lactamases. J Biol Chem (2003) 1.03
Doripenem monohydrate, a broad-spectrum carbapenem antibiotic. Clin Ther (2009) 1.03
Probing the role of Asp-120(81) of metallo-beta-lactamase (IMP-1) by site-directed mutagenesis, kinetic studies, and X-ray crystallography. J Biol Chem (2005) 1.02
Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections. Clin Infect Dis (2008) 1.01
Shape signatures: new descriptors for predicting cardiotoxicity in silico. Chem Res Toxicol (2008) 1.01
Molecular dynamics simulations of the mononuclear zinc-beta-lactamase from Bacillus cereus complexed with benzylpenicillin and a quantum chemical study of the reaction mechanism. J Am Chem Soc (2001) 1.00
Comparative study of the inhibition of metallo-beta-lactamases (IMP-1 and VIM-2) by thiol compounds that contain a hydrophobic group. Biol Pharm Bull (2004) 1.00
Inhibition of metallo-beta-lactamases by a series of thiol ester derivatives of mercaptophenylacetic acid. FEMS Microbiol Lett (1997) 1.00
A review of the antimicrobial activity of clavulanate. J Antimicrob Chemother (2003) 1.00
Ertapenem: a review of its use in the treatment of bacterial infections. Drugs (2005) 0.99
Hydroxyl groups in the (beta)beta sandwich of metallo-beta-lactamases favor enzyme activity: a computational protein design study. J Mol Biol (2005) 0.99
Thiols as classical and slow-binding inhibitors of IMP-1 and other binuclear metallo-beta-lactamases. Biochemistry (2003) 0.99
Global resistance trends and the potential impact on empirical therapy. Int J Antimicrob Agents (2008) 0.99
Computational discovery of novel low micromolar human pregnane X receptor antagonists. Mol Pharmacol (2008) 0.98
Metallo-beta-lactamase IMP-18 is located in a class 1 integron (In96) in a clinical isolate of Pseudomonas aeruginosa from Mexico. Int J Antimicrob Agents (2007) 0.98
N-arylsulfonyl hydrazones as inhibitors of IMP-1 metallo-beta-lactamase. Antimicrob Agents Chemother (2002) 0.97
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila. Antimicrob Agents Chemother (2007) 0.96
Integron-associated imipenem resistance in Acinetobacter baumannii isolated from a regional hospital in Taiwan. Int J Antimicrob Agents (2005) 0.96
Development and application of hybrid structure based method for efficient screening of ligands binding to G-protein coupled receptors. J Comput Aided Mol Des (2006) 0.95
Metallo-beta-lactamase inhibitory activity of phthalic acid derivatives. Bioorg Med Chem Lett (2009) 0.95
Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res (2003) 3.72
Highly chlorinated PCBs inhibit the human xenobiotic response mediated by the steroid and xenobiotic receptor (SXR). Environ Health Perspect (2004) 2.16
Bisphenol A and its analogues activate human pregnane X receptor. Environ Health Perspect (2012) 1.81
Lack of androgenicity and estrogenicity of the three monomers used in Eastman's Tritan™ copolyesters. Food Chem Toxicol (2012) 1.76
Online chemical modeling environment (OCHEM): web platform for data storage, model development and publishing of chemical information. J Comput Aided Mol Des (2011) 1.68
Gaussian mixture clustering and imputation of microarray data. Bioinformatics (2004) 1.49
Shape signatures: a new approach to computer-aided ligand- and receptor-based drug design. J Med Chem (2003) 1.39
Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. Mol Pharmacol (2007) 1.39
Detecting hidden sequence propensity for amyloid fibril formation. Protein Sci (2004) 1.25
DNA microarray data imputation and significance analysis of differential expression. Bioinformatics (2005) 1.24
Oleic acid and peanut oil high in oleic acid reverse the inhibitory effect of insulin production of the inflammatory cytokine TNF-alpha both in vitro and in vivo systems. Lipids Health Dis (2009) 1.21
New predictive models for blood-brain barrier permeability of drug-like molecules. Pharm Res (2008) 1.20
Highly potent triazole-based tubulin polymerization inhibitors. J Med Chem (2007) 1.13
Improved method for predicting beta-turn using support vector machine. Bioinformatics (2005) 1.10
Evolution of the bile salt nuclear receptor FXR in vertebrates. J Lipid Res (2008) 1.08
Ligand specificity and evolution of liver X receptors. J Steroid Biochem Mol Biol (2008) 1.06
Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: structure-activity relationship and molecular-modeling studies. Biochem Pharmacol (2005) 1.04
Shape Signatures: speeding up computer aided drug discovery. Drug Discov Today (2006) 1.03
Quantitative structure-activity relationship methods: perspectives on drug discovery and toxicology. Environ Toxicol Chem (2003) 1.03
Requirement of activated Cdc42-associated kinase for survival of v-Ras-transformed mammalian cells. Mol Cancer Res (2005) 1.03
Shape signatures: new descriptors for predicting cardiotoxicity in silico. Chem Res Toxicol (2008) 1.01
Using surrogate modeling in the prediction of fibrinogen adsorption onto polymer surfaces. J Chem Inf Comput Sci (2004) 1.00
Enrichment of ligands for the serotonin receptor using the Shape Signatures approach. J Chem Inf Model (2005) 1.00
Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction. Biopolymers (2003) 0.99
Structure-based design of novel small-molecule inhibitors of Plasmodium falciparum. J Chem Inf Model (2010) 0.99
Computational discovery of novel low micromolar human pregnane X receptor antagonists. Mol Pharmacol (2008) 0.98
Prediction of the orientations of adsorbed protein using an empirical energy function with implicit solvation. Langmuir (2005) 0.98
Wavelet analysis of DNA walks. J Comput Biol (2006) 0.98
Carbohydrate composition of amphiphilic macromolecules influences physicochemical properties and binding to atherogenic scavenger receptor A. Acta Biomater (2012) 0.97
A new approach to the rationale discovery of polymeric biomaterials. Biomaterials (2007) 0.96
Advancing human rights through science. Science (2009) 0.95
Development and application of hybrid structure based method for efficient screening of ligands binding to G-protein coupled receptors. J Comput Aided Mol Des (2006) 0.95
Novel microtubule polymerization inhibitor with potent antiproliferative and antitumor activity. Cancer Res (2009) 0.93
Identification of a minimal subset of receptor conformations for improved multiple conformation docking and two-step scoring. J Chem Inf Comput Sci (2004) 0.93
Rapid assessment of contact-dependent secondary structure propensity: relevance to amyloidogenic sequences. Proteins (2005) 0.92
Structure-activity relationship approaches and applications. Environ Toxicol Chem (2003) 0.92
Prediction of Fibrinogen Adsorption for Biodegradable Polymers: Integration of Molecular Dynamics and Surrogate Modeling. Polymer (Guildf) (2007) 0.92
NetCSSP: web application for predicting chameleon sequences and amyloid fibril formation. Nucleic Acids Res (2009) 0.92
Three-dimensional structure-activity relationship modeling of cocaine binding to two monoclonal antibodies by comparative molecular field analysis. J Mol Biol (2003) 0.90
Potent inhibitors of human organic anion transporters 1 and 3 from clinical drug libraries: discovery and molecular characterization. Mol Pharm (2012) 0.89
Identification of previously unrecognized antiestrogenic chemicals using a novel virtual screening approach. Chem Res Toxicol (2006) 0.89
In silico design of anti-atherogenic biomaterials. Biomaterials (2013) 0.89
Elucidation of the Na+, K+-ATPase digitalis binding site. J Mol Graph Model (2005) 0.89
The evolution of farnesoid X, vitamin D, and pregnane X receptors: insights from the green-spotted pufferfish (Tetraodon nigriviridis) and other non-mammalian species. BMC Biochem (2011) 0.89
Novel IMP-1 metallo-beta-lactamase inhibitors can reverse meropenem resistance in Escherichia coli expressing IMP-1. FEMS Microbiol Lett (2005) 0.88
Hybrid scoring and classification approaches to predict human pregnane X receptor activators. Pharm Res (2008) 0.88
The major human pregnane X receptor (PXR) splice variant, PXR.2, exhibits significantly diminished ligand-activated transcriptional regulation. Drug Metab Dispos (2009) 0.87
Salicylanilide inhibitors of Toxoplasma gondii. J Med Chem (2012) 0.87
Unique helical conformation of the fourth cytoplasmic loop of the CB1 cannabinoid receptor in a negatively charged environment. J Struct Biol (2007) 0.86
CSSP2: an improved method for predicting contact-dependent secondary structure propensity. Comput Biol Chem (2007) 0.85
Combining (1)H NMR spectroscopy and chemometrics to identify heparin samples that may possess dermatan sulfate (DS) impurities or oversulfated chondroitin sulfate (OSCS) contaminants. J Pharm Biomed Anal (2010) 0.84
Metallo-beta-lactamase inhibitors: could they give old antibacterials new life? Curr Opin Investig Drugs (2003) 0.84
Predicting inhibitors of acetylcholinesterase by regression and classification machine learning approaches with combinations of molecular descriptors. Pharm Res (2009) 0.84
Three-dimensional quantitative structure-activity relationship study of the inhibition of Na(+),K(+)-ATPase by cardiotonic steroids using comparative molecular field analysis. Biochemistry (2002) 0.84
Interaction of organophosphate pesticides and related compounds with the androgen receptor. Environ Health Perspect (2003) 0.83
Highly predictive CoMFA and CoMSIA models for two series of stromelysin-1 (MMP-3) inhibitors elucidate S1' and S1-S2' binding modes. J Chem Inf Model (2006) 0.83
Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor. J Med Chem (2002) 0.83
Structural characterization of the zinc binding domain in cytosolic PSD-95 interactor (cypin): Role of zinc binding in guanine deamination and dendrite branching. Proteins (2008) 0.83
3D-QSAR comparative molecular field analysis on opioid receptor antagonists: pooling data from different studies. J Med Chem (2005) 0.83
Application of screening methods, shape signatures and engineered biosensors in early drug discovery process. Pharm Res (2009) 0.83
LTMap: a web server for assessing the potential liver toxicity by genome-wide transcriptional expression data. J Appl Toxicol (2013) 0.82
Discovery of novel triazole-based opioid receptor antagonists. J Med Chem (2006) 0.82
Relating anatomical therapeutic indications by the ensemble similarity of drug sets. J Chem Inf Model (2013) 0.82
Progenetix: 12 years of oncogenomic data curation. Nucleic Acids Res (2013) 0.82
Halogenated ligands and their interactions with amino acids: implications for structure-activity and structure-toxicity relationships. J Mol Graph Model (2008) 0.82
Pregnane X receptor mediates dyslipidemia induced by the HIV protease inhibitor amprenavir in mice. Mol Pharmacol (2013) 0.81
A preliminary in silico lead series of 2-phthalimidinoglutaric acid analogues designed as MMP-3 inhibitors. J Chem Inf Model (2006) 0.81
Human ADA3 regulates RARalpha transcriptional activity through direct contact between LxxLL motifs and the receptor coactivator pocket. Nucleic Acids Res (2010) 0.81
Dissecting active ingredients of Chinese medicine by content-weighted ingredient-target network. Mol Biosyst (2014) 0.81
Determination of galactosamine impurities in heparin samples by multivariate regression analysis of their (1)H NMR spectra. Anal Bioanal Chem (2010) 0.81
Two farnesoid X receptor alpha isoforms in Japanese medaka (Oryzias latipes) are differentially activated in vitro. Aquat Toxicol (2010) 0.81
Three-dimensional quantitative structure-property relationship (3D-QSPR) models for prediction of thermodynamic properties of polychlorinated biphenyls (PCBs): enthalpies of fusion and their application to estimates of enthalpies of sublimation and aqueous solubilities. J Chem Inf Comput Sci (2003) 0.80
ebTrack: an environmental bioinformatics system built upon ArrayTrack. BMC Proc (2009) 0.80
Structural model reveals key interactions in the assembly of the pregnane X receptor/corepressor complex. Mol Pharmacol (2006) 0.80
Understanding nuclear receptors using computational methods. Drug Discov Today (2009) 0.80
3D-QSAR comparative molecular field analysis on delta opioid receptor agonist SNC80 and its analogs. J Mol Graph Model (2005) 0.80
Identification of small molecule compounds with higher binding affinity to guanine deaminase (cypin) than guanine. Bioorg Med Chem (2010) 0.80
Age dependence of glucose tolerance in adult KK-Ay mice, a model of non-insulin dependent diabetes mellitus. Lab Anim (NY) (2009) 0.79
Volume learning algorithm significantly improved PLS model for predicting the estrogenic activity of xenoestrogens. J Mol Graph Model (2007) 0.78
Purposeful learning with drug repurposing. Science (2009) 0.78
Influence of the structural diversity of data sets on the statistical quality of three-dimensional quantitative structure-activity relationship (3D-QSAR) models: predicting the estrogenic activity of xenoestrogens. Chem Res Toxicol (2002) 0.78
Identification of possible kinetically significant anion-binding sites in human serum transferrin using molecular modeling strategies. Biopolymers (2004) 0.78
Three-dimensional quantitative structure--property relationship (3D-QSPR) models for prediction of thermodynamic properties of polychlorinated biphenyls (PCBs): enthalpy of sublimation. J Chem Inf Comput Sci (2002) 0.78
Evaluation of broad spectrum protein kinase inhibitors to probe the architecture of the malarial cyclin dependent protein kinase Pfmrk. Bioorg Med Chem Lett (2007) 0.78
Identification of heparin samples that contain impurities or contaminants by chemometric pattern recognition analysis of proton NMR spectral data. Anal Bioanal Chem (2011) 0.78
Computational models for predicting the binding affinities of ligands for the wild-type androgen receptor and a mutated variant associated with human prostate cancer. Chem Res Toxicol (2003) 0.78
Expression, purification, crystallization and preliminary X-ray analysis of Aeromonas hydrophilia metallo-beta-lactamase. Acta Crystallogr Sect F Struct Biol Cryst Commun (2005) 0.77
Three-dimensional structure-activity relationship modeling of digoxin inhibition and docking to Na+,K+-ATPase. Ann N Y Acad Sci (2003) 0.77